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Summary
Peutz-Jeghers syndrome (PJS) is an autosomal dominant
disease characterized by mucocutaneous pigmentation
and hamartomatous polyps. There is an increased risk
of benign and malignant tumors in the gastrointestinal
tract and in extraintestinal tissues. One PJS locus has
been mapped to chromosome 19p13.3; a second locus
is suspected on chromosome 19q13.4 in a minority of
families. The PJS gene on 19p13.3 has recently been
cloned, and it encodes the serine/threonine kinase LKB1.
The gene, which is ubiquitously expressed, is composed
of 10 exons spanning 23 kb. Several LKB1 mutations
have been reported in heterozygosity in PJS patients. In
this study, we screened for LKB1 mutations in nine PJS
families of American, Spanish, Portuguese, French,
Turkish, and Indian origin and detected seven novel mu-
tations. These included two frameshift mutations, one
four-amino-acid deletion, two amino-acid substitutions,
and two splicing errors. Expression of mutant LKB1
proteins (K78I, D176N, W308C, and L67P) and as-
sessment of their autophosphorylation activity revealed
a loss of the kinase activity in all of these mutants. These
results provide direct evidence that the elimination of
the kinase activity of LKB1 is probably responsible for
the development of the PJS phenotypes. In two Indian
families, we failed to detect any LKB1 mutation; in one
of these families, we previously had detected linkage to
markers on 19q13.3–4, which suggests locus heteroge-
neity of PJS. The elucidation of the molecular etiology
of PJS and the positional cloning of the second potential
PJS gene will further elucidate the involvement of ki-
nases/phosphatases in the development of cancer-pre-
disposing syndromes.
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Introduction
Peutz-Jeghers syndrome (PJS; MIM 175200) is a rare
autosomal dominant disease characterized by mucocu-
taneous pigmentation and gastrointestinal hamartoma-
tous polyposis (Peutz et al. 1921; Jeghers et al. 1949).
Patients with PJS demonstrate a high risk for gastro-
intestinal and extraintestinal cancers (ovaries, testes,
breast, and uterine cervix; Giardiello et al. 1987; Spi-
gelman et al. 1989). In addition, benign ovarian tumors
may occur in female PJS patients. One locus for PJS has
been mapped to chromosome 19p13.3, in the vicinity
of marker D19S886, by comparative genomic hybridiza-
tion and linkage studies (Hemminki et al. 1997), and
subsequently has been confirmed by other investigators
(Amos et al. 1997; Mehenni et al. 1997; Olschwang et
al. 1998; Nakagawa et al. 1998). In the sample of six
PJS families studied by Mehenni et al. (1997), a potential
second PJS locus, on 19q13.4, in the vicinity of marker
D19S891, was suggested. The presumed locus hetero-
geneity of PJS has also been observed in the sample stud-
ied by Olschwang et al. (1998), in which not all families
showed linkage to 19p13.3.
In recent studies, the PJS gene on 19p13.3 has been
identified (Hemminki et al. 1998; Jenne et al. 1998). Two
groups discovered mutations in the LKB1, or STK11,
gene in patients with PJS. This gene encodes a potential
serine/threonine kinase, first cloned by J.-i. Nezu (un-
published data; Genbank entry U63333), that shows
strong homology with the cytoplasmic serine/threonine
kinase XEEK1 of Xenopus laevis (Su et al. 1996) and
shows weaker similarity to many other protein kinases.
The 10 exons of LKB1 span 23 kb of genomic DNA,
and the gene is expressed ubiquitously in all human tis-
sues (Jenne et al. 1998). Most of the LKB1 mutations
identified in PJS are null alleles (including nonsense co-
dons, deletions, insertions, and rearrangements), and
only one missense mutation, L67P, has been observed
(Hemminki et al.1998; Jenne et al. 1998). It is likely that
LKB1 is a tumor-suppressor gene, since loss of the nor-
mal allele was observed in the polyps from a PJS patient
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with a germ-line mutation on the other allele (Hemminki
et al. 1998). In more-recent studies, loss of heterozy-
gosity and a somatic mutation (G163D) have been ob-
served in some tumor tissues (Avizienyte et al. 1998;
Bignell et al. 1998).
To contribute to the study of the molecular patho-
physiology of PJS and, thus, to the study of cancer pre-
disposition, we analyzed the occurrence of gene muta-
tions in nine families, using single-strand conformation
analysis (SSCA) and sequencing. Mutations were found
in heterozygosity in seven of these families, including
two missense substitutions. We also show that the mu-
tant LKB1 proteins with these amino acid substitutions
lost their kinase activity, as measured by the rate of au-
tophosphorylation. Our data also support the locus het-
erogeneity of PJS, because one of the two families in
which an LKB1 mutation was not found showed strong
evidence for linkage to a genomic region on 19q13.4.
Families and Methods
Families with PJS
Samples of genomic DNA from individuals of nine
families that met the clinical criteria (Mehenni et al.
1997) of PJS were isolated from peripheral blood lym-
phocytes by standard methods. The study was approved
by the appropriate ethics committee, and the samples
from all families that participated in the study were col-
lected after informed consent was obtained from the par-
ticipants. The pedigrees of six of these families (PJS01
and PJS03 from Spain, PJS05 from Utah, PJS06 from
Portugal, and PJS07 and PJS08 from India) have been
published elsewhere (Mehenni et al. 1997). The addi-
tional three families were from Turkey (PJS02), France
(PJS04), and Tahiti (PJS09). All families had multiple
affected individuals, except family PJS02, in which there
was only one affected member.
SSCA Analysis, Southern Blot, and Sequencing
Genomic DNA from at least one affected individual
per family was PCR-amplified for eight different ge-
nomic regions that covered the entire coding sequence
of the LKB1 gene and all of the splice junctions. The
oligonucleotide primers used and the conditions for PCR
amplification were as described by Jenne et al. (1998).
For SSCA, the PCR products were denatured with an
equal volume of denaturation buffer (95% formamide,
0.05% xylene cyanol, and 0.05% bromophenol blue)
for 10 min at 94C, and 4 ml were then loaded onto a
12.5% GeneGel Excel (Pharmacia Biotech). Electropho-
resis was at 600 V at 12C for 2–3 h, depending on the
size of the PCR product. The gels were stained by DNA
silver staining (Pharmacia Biotech). SSCA variants were
purified with QIAquick spin columns and were directly
sequenced, in both directions, with the appropriate
primers on an ABI377 sequencer, by use of standard
protocols. Primer sequences are available on request
(Hamid.Mehenni@medecine.unige.ch). Because of the
autosomal dominant nature of the disease and, there-
fore, the heterozygosity of the mutations in patients’
DNA, all mutant alleles were also cloned by the Original
TA cloning kit (Invitrogen) and were purified and se-
quenced as previously described. In order to distinguish
between polymorphisms and disease-causing mutations,
a panel of 100 normal, unrelated Caucasian individuals
was screened for some of the sequence variants described
here, by either restriction-endonuclease analysis or
SSCA. The numbering of the nucleotide changes de-
scribed in the present article are in accordance with the
LKB1 cDNA sequence (Genbank U63333). Genomic
Southern blots were prepared after endonuclease diges-
tion with EcoRI, HindIII, and BamHI/PstI and were
probed with a cloned cDNA fragment that comprised
the entire coding region of LKB1.
Construction of Expression Vectors
The expression plasmid DNA, pcDNA3/LKB1 myc,
which contained the wild-type LKB1 coding sequence
and c-myc epitope tag (EQKLISEEDL) on its carboxyl
terminal, was constructed by PCR, as follows. A DNA
fragment amplified by PCR, by use of an LKE1 primer
(5′ gat gaa ttc ggg tcc agc atg gag gtg gtg gac 3′) and an
LKE2 primer (5′ gat gaa ttc tta gag gtc ttc ttc tga gat
gag ctt ctg ctc ctg ctg ctt gca ggc cga 3′), was cloned into
an EcoRI site of pcDNA3 vector (Invitrogen). The clones
with the correct orientation were selected, and their se-
quences were verified.
Each of the mutant plasmids (pcDNA3/LKB1-K78I-
myc, pcDNA3/LKB1-D176N-myc, pcDNA3/LKB1-
W308C-myc, and pcDNA3/LKB1-L67P-myc) were
generated from this clone by in vitro mutagenesis, by
the GENEEDITOR in vitro site-directed mutagenesis
system (Promega), in accordance with the procedure sug-
gested by the manufacturer. The mutagenic oligonucleo-
tides, LK K78I (5′ agg agg gcc gtc atc atc ctc aag aag
3′), LK D176N (5′ att gtg cac aag aac atc aag ccg ggg
3′), LK W308C (5′ cgg cag cac agc tgc ttc cgg aag aaa
3′), and LK L67P (5′ gtg aag gag gtg ccg gac tcg gag acg
3′), were hybridized to single-stranded pcDNA3/LKB1
myc plasmid DNA with the selection oligonucleotide
(bottom strand), and mutant strands were synthesized.
The plasmid DNAs with the introduced mutations were
selected by use of the GENEEDITOR-produced antibi-
otic-resistant clone, and the mutations were confirmed
by sequencing.
cDNA Expression and Kinase Assay
Ten micrograms of DNA from each of the four mutant
and normal constructs were transformed into 106 COS7
cells by SuperFect Transfection Reagent (Qiagen). The
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Table 1
Mutations in the LKB1 Gene in PJS Families Described in the
Present Study
FAMILY
MUTATION IN
DNA Protein
PJS01 Exon 1, 151–168del18,
150–151ins6
Del LMGD 50–53
PJS02 Exon 4, 574–575insA Frameshift, 73 new amino
acids after K191
PJS03 IVS55GrA Abnormal splicing and
truncated protein
PJS04 Exon 8, 924GrT W308C
PJS05 Exon 4, 526GrA D176N
PJS06 Exon 7, 903delG Frameshift, 33 new amino
acids after R301
PJS07 No mutation detected
PJS08 No mutation detected
PJS09 IVS6 and exon 7, del52
ending at 904
Abnormal splicing and
truncated protein
transfected cells were incubated for 48 h and were ex-
tracted in an NP40 kinase lysis buffer (10 mM Tris-Cl
[pH 7.8], 1% NP40, 0.15 M NaCl, 1 mM EDTA, 50
mM NaF, 5 mM sodium diphosphate, 10 mg/ml apro-
tinin, and 1 mM phenylmethylsulfonyl fluoride) at 4C.
Cell lysates were precleared by mixing with protein A/
G plus agarose (Santa Cruz) for 30 min, and then the
transiently expressed proteins were immunoprecipitated
with an anti–c-myc antibody, A14 (Santa Cruz). Precip-
itates were washed six times with an NP40 kinase lysis
buffer containing 0.15 or 1 M NaCl, followed by one
wash in 50 mM Tris-Cl (pH 7.8). For the kinase assays,
samples were resuspended in 50 ml of 50 mM Tris-Cl
pH 7.8, 1 mM DTT, 10 mM MnCl2, and g[
32P]-ATP (10
mCi) and incubated at 37C for 30 min. The reaction
was stopped by the addition of the SDS sampling buffer,
and the samples were incubated at 95C for 5 min. Prod-
ucts of the reaction were subjected to SDS-PAGE and
were visualized by autoradiography. Expressed normal
and mutant proteins in the lysates were quantified by
western blotting using the anti–c-myc antibody A14.
Protein Modeling
Crystallized proteins homologous to LKB1 were iden-
tified by SWISS-MODEL (Peitsch 1996). Three protein
kinases sharing enough sequence identity with LKB1 to
be used as templates for the construction of a model
were retained: PBD entries 1ATP (Zheng et al. 1993),
1KOB (Kobe et al. 1996; Heierhorst et al. 1996), and
1AQ1 (Lawrie et al. 1997). Those kinases share 26%,
22%, and 22% identity and 50%, 43%, and 39% sim-
ilarity with LKB1, respectively, over residues Y49–I360
of LKB1.
The three crystallized proteins were superimposed in
three-dimensional space by use of SWISS-PDBVIEWER
(Guex and Peitsch 1997), and the primary sequence of
LKB1 was aligned onto the three templates. Residues
Y49–I360 of LKB1 were built by use of the average of
the backbone position of the three templates, as de-
scribed by Blundell et al. (1987), and by the addition of
the side chains from a rotamer library (Ponder and Rich-
ards 1987), so that they matched as closely as possible
those present in the three templates. Protein 1ATP was
used as the main template, whereas 1KOB and 1AQ1
were used as auxiliary templates. Since LKB1 could not
be aligned onto the three templates without gaps, some
residues could not be built by homology, and those loops
had to be rebuilt de novo in SWISS-PDBVIEWER. The
loops that best matched to the corresponding region of
the templates while registering a favorable energy read-
ing were selected. Next, one ATP and two Mn mol-
ecules were introduced in the same location as those
present in the PDB file 1ATP, and the model was opti-
mized by cycles of steepest descent, followed2# 100
by cycles of conjugate gradients, by use of3# 200
CHARMM (Brooks et al. 1983). The same procedure
was followed to build models with amino acid substi-
tutions D139N and K78I.
Results and Discussion
LKB1 Mutations
The recent discovery that mutations in the LKB1 gene
are responsible for most of the cases of PJS (Hemminki
et al. 1998; Jenne et al. 1998) prompted us to examine
the molecular defects present in our collection of nine
families with this syndrome, explore the possibility of
locus heterogeneity, and study the importance of the ki-
nase activity of LKB1 in the pathophysiology of the dis-
ease. We used a combination of methods, such as SSCA,
Southern blot analysis, and nucleotide sequencing, to
search for LKB1 mutations.
Seven novel LKB1 mutations were detected in the ge-
nomic DNA samples of seven families (table 1 and figs.
1 and 2); in the remaining two families, no mutations
were identified. Four of these mutations—three deletions
and one mutation in a splice site—are likely to result in
a translational frameshift and, thus, premature termi-
nation of LKB1. Two mutations cause amino acid sub-
stitutions, and one results in the deletion of four amino
acids.
The first mutation (fig. 1A) is a single-base (A) inser-
tion between nucleotides 574 and 575 of exon 4 of LKB1
and was found in heterozygosity in a sporadic case in a
Turkish PJS patient (PJS02). This insertion introduces a
frameshift at codon K191, 73 novel amino acids, and
the premature termination of a 265-residue protein com-
pared with the normal 433 amino-acid protein. The
DNA from both parents of the affected individual did
not have this mutation, which is therefore a de novo
mutation. In addition, none of the nine siblings carried
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Figure 1 Nucleotide sequences of the LKB1 mutations identified in the present study. Sequences are in pairs, which include the normal
sequence (left) and the mutant sequence (right). The identity of the PJS family in which each mutation was found is denoted above each mutant
sequence. The sequences of the mutant alleles were obtained after cloning of the PCR products (see Families and Methods).
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Figure 2 Schematic representation of the LKB1 gene (top) and protein (bottom). The exons are depicted as striped boxes; the intron sizes
are not to scale. The different subdomains (I–IX) of the kinase domain of LKB1, as described by Hanks and Hunter 1995, are depicted (bottom).
The mutations described in the present study are shown above the genomic structure. The amino acid substitutions or deletions are also shown
in the schematic of the predicted protein. The amino acid lesions shown in italics have been described by Avizienyte et al. (1998) and Hemminki
et al. (1998). The mutation in italics and underlined has been described in the Xenopus XEEK1 (Su et al. 1996).
Figure 3 Autophosphorylation assays of the wild-type and mu-
tant LKB1 recombinant proteins, as described in Families and Meth-
ods. The lower panel shows the results of western blotting by use of
the anti-myc antibody. The top panel reveals that the wild-type LKB1
is autophosphorylated, whereas the same amount of each of the mu-
tants tested, including the K78I, D176N, W308C, and L67P, shows
either no or dramatically reduced autophosphorylation.
the mutation, which makes it unlikely that there was a
parental mosaicism for this molecular defect. The inser-
tion of A occurred in a run of four A’s, which is com-
monplace in insertional mutagenesis, and is potentially
a result of polymerase pause and of frameshifting (Coo-
per et al. 1995). No cancer has been reported in this
patient.
The second mutation (fig. 1B) is a deletion of one
nucleotide (903G) in exon 7 of LKB1, found in hetero-
zygosity in affected individuals of a Portuguese family
(PJS06). This results in a frameshift after codon R301,
the introduction of 33 novel amino acids, and the pre-
mature termination of a 335-amino-acid protein. All
eight affected individuals in this family were heterozy-
gotes for 903delG, and none of their 17 normal relatives
who were examined showed the mutation in their DNA
samples taken from blood lymphocytes. No cancers were
reported in the affected members of this family.
The third mutation (fig. 1C) is a deletion of 52 bp at
the end of intron 6, which includes the majority of exon
7, that was found in a Tahitian family (PJS09). This
deletion ends at nucleotide 904 of the LKB1 cDNA in
exon 7 and probably results in abnormal splicing and
truncated protein. The deleted DNA is flanked by a pen-
tanucleotide direct repeat, CCGGC, and therefore the
mechanism of this deletion is compatible with the
slipped-mispairing model (Cooper et al. 1995). Only one
affected individual from this family was available for
DNA analysis; this patient had developed colon carci-
noma. In addition, two of his siblings with PJS had died
from gastrointestinal carcinomas. The mutation was not
found in the DNAs of four available normal relatives.
The fourth mutation (fig. 1D) was a GrA substitution
at nucleotide 5 of the consensus donor splice site of
1646 Am. J. Hum. Genet. 63:1641–1650, 1998
Figure 4 Stereo images of the catalytic core of LKB1 in the presence of ATP after modeling (see Families and Methods). The normal
LKB1 is shown in the middle, for easier comparison with the mutants; the D176N mutant is on the top, and the K78I is on the bottom. The
protein backbone is shown in blue, whereas side chains and ATP are shown in the following colors: C, white; O, red; N, blue; P, orange; S,
yellow; H, cyan. Two Mn atoms are shown as gray balls. Both mutations greatly disrupt the normal chemical contacts in the catalytic core
(see the Protein Modeling subsection).
intron 5 of the LKB1 gene and was found in a Spanish
family (PJS03). This substitution was observed in all five
affected siblings, and there is no history of carcinomas
in this family. The mutation is likely to result in abnor-
mal splicing and a truncated protein, because G is the
preferred (85% frequency) nucleotide at position 5 of
the splice site (Padgett et al. 1986). The mutation is not
a common polymorphism, since it was not detected in
100 normal Caucasians. The Human Gene Mutation
database at the Institute of Medical Genetics in Cardiff
contains many mutations at nucleotide 5 of the donor
splice site that are predicted to reduce significantly the
stability of the splice-site base pairing with the comple-
mentary region of U1 snRNA (Cooper et al. 1995). No
cancers were reported in the affected members of this
family.
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Figure 5 Overall fold of the LKB1 protein modeling. The b-
strand that would be removed by the deletion of tetrapeptide LMGD
is shown in red. ATP is added in the catalytic core. The D176 side
chain that is mutated in family PJS05 is shown in green. The side chain
of K78 is shown in purple. The W308 side chain mutated in PJS04
and in C158, which probably forms a disulfide bridge with the mutant
W308C, is shown in black. L67, which is mutated to L67P (Hemminki
et al. 1998), is shown in yellow.
The fifth mutation (fig. 1E) is a combination of a
deletion of 18 nucleotides in exon 1 and an insertion of
6 nucleotides at the site of the deletion, which was ob-
served in a Spanish family (PJS01). The mechanism of
this complex mutation is unclear; however, it is note-
worthy that at the site of the deletion there is a direct
repeat of seven nucleotides (TG5A). The net result is the
deletion of four amino acids, LMGD in codons 50–53
of LKB1, because the inserted six nucleotides code for
the same amino acids normally present at this position
in the protein. The deleted amino acids are within the
protein kinase ATP-binding region (subdomain I in
Hanks and Hunter 1995; Prosite domain PDOC00100,
PS00107), and therefore the mutant protein is likely to
be nonfunctional. All 10 affected individuals were het-
erozygous for this mutation, and none of their 12 normal
relatives who were examined carried this molecular de-
fect. No cancers were reported in the affected members
of this family.
The sixth mutation (fig. 1F) was a nucleotide change,
526GrA in exon 4 of the LKB1 gene, that resulted in
the substitution of Asp176 by Asn (D176N), which was
found in an American Caucasian family from Utah
(PJS05). This substitution occurs within the serine/thre-
onine protein kinase active-site signature (Prosite do-
main PDOC00100, PS00108; subdomain VIb in Hanks
and Hunter 1995). Asp176 is an invariant amino acid
of this active site (catalytic loop) that is important for
the catalytic activity of the enzyme; it is likely that
Asp176 accepts the proton from the attacking substrate
hydroxyl group during the phosphotransfer mechanism
(Hanks and Hunter 1995). The mutation was not de-
tected in 100 normal Caucasians. All five affected in-
dividuals studied were heterozygous for D176N, and
none of their eight normal relatives who were examined
carried this molecular defect. Affected members of this
family had developed cancers (pancreatic and other gas-
trointestinal neoplasias).
The seventh mutation (fig. 1G), found in a French
family (PJS04), was a nucleotide change, 924GrT in
exon 8, that resulted in the substitution of Trp308 by
Cys (W308C). This substitution does not occur in a rec-
ognizable domain of LKB1, but it is likely to be a path-
ogenic mutation, since it was not detected in 100 normal
Caucasians. The introduction of a novel Cys308 may
result in a dramatic change of the three-dimensional
structure of LKB1 and in the elimination of its normal
activity (see the Loss of Protein Kinase Activity of Mu-
tant LKB1 in PJS Patients subsection ). All three affected
individuals studied were heterozygous for this W308C,
and none of their two normal relatives examined carried
this molecular defect. No cancers were reported in the
affected members of this family.
Loss of Protein Kinase Activity of Mutant LKB1 in PJS
Patients
To study the protein kinase activity of certain mutant
LKB1 proteins, we produced, by transient expression in
COS7 cells, normal and mutant LKB1s, all tagged at
their carboxyl-terminal ends with a 10-amino-acid c-
myc epitope. The four mutant LKB1 proteins made were
those with (1) the D176N mutation (identical to the
mutation in family PJS05, described in the LKB1 Mu-
tations subsection), (2) the W308C substitution (iden-
tical to the mutation in family PJS04, described in the
LKB1 Mutations subsection), (3) the L67P substitution
(identical to the mutation in PJS family SL25, reported
by Hemminki et al. 1998), and (4) the K78I substitution
that corresponds to the mutation in the subdomain II
ATP-binding site of the Xenopus XEEK1 protein and
that was previously shown to abolish the XEEK1 au-
tophosphorylation (Su et al. 1996). The protein kinase
activities of the normal and mutant LKB1s were assayed
by autophosphorylation, as previously had been per-
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formed for the LKB1 Xenopus homologue, XEEK1. As
shown in figure 3, although equal amounts of each pro-
tein were assayed (as shown by the anti-myc staining of
the hybrid proteins), no or very little autophosphory-
lation was observed in all four mutant LKB1s compared
with normal samples, which clearly shows the loss of
kinase activity of LKB1. Thus, this biochemical defect
is probably associated with the development of the dif-
ferent phenotypes in neoplasia-susceptibility PJS, but
further studies are needed to prove this conclusion. The
autophosphorylation defect was expected in LKB1 mu-
tants D176N and K81I, since these amino acid substi-
tutions occur in important residues of the kinase family
of proteins (Hanks and Hunter 1995). The other two
mutations (i.e., L67P and W308C) do not occur in rec-
ognized functional domains of the kinases, but they are
likely to disrupt the normal three-dimensional structure
and folding of LKB1. Therefore, LKB1 is the first known
protein kinase that predisposes to cancer because of loss
of the kinase activity, since the germ-line mutations in
other protein kinase–encoding genes, such as RET (Eng
and Mulligan 1997), MET (Schmidt et al. 1997), and
CDK4 (Zuo et al. 1996), are associated with predis-
position to neoplasia when mutations result in activation
of kinase activity.
Polymorphic Variability of the LKB1 Gene
During the search for LKB1 mutations, the following
polymorphic variants were also identified: a single-nu-
cleotide polymorphism, 1315ArG in IVS2 (nucleotide
numbering is that of Genbank entry AF032985), and
another single-nucleotide polymorphism, 4053GrC in
IVS7 (nucleotide numbering is that of Genbank entry
AF032985), both of which were present in normal and
affected individuals of different ethnic origins; and a
short sequence repeat of the heptamer GGGGGCC
(starting at nucleotide 1486 of Genbank entry
AF032985) in IVS3, which is polymorphic, with two or
three allelic tandem copies in the population. These poly-
morphisms may be of use in linkage studies of chro-
mosome 19p13.3.
Protein Modeling
Computer models of LKB1 were generated for normal
LKB1 and two of the mutants. Although these models
are only computer approximations of changes that might
occur in the tertiary structure, they aid in the under-
standing of the role of this kinase in PJS. Figure 4 shows
the catalytic core of these three models—one normal,
one with the PJS mutation D176N, and one with the
K78I mutation that abolishes the autophosphorylation
in the Xenopus XEEK1 gene (Su et al. 1996). The
D176N mutation is likely to prevent a proper catalysis
(fig. 4, top). Indeed, the phosphate group transferred
during the phosphorylation of the target protein is very
close to D176, which is probably crucial to maintain the
phosphate group in a proper location for its transfer. In
addition, the negative charge seems to be effective to
maintain K178 close to the phosphate groups. This ly-
sine is conserved among the kinases and is important
for the catalysis. The mutation of the invariant K78I is
also likely to prevent proper catalysis (fig. 4, bottom).
K78 helps to anchor and orient ATP and also forms an
important salt bridge with the carboxyl group of the
nearly invariant E98. In the model with I78, this bridge
is not formed.
The deletion of tetrapeptide LMGD (codons 50–53
of LKB1) is likely to have a major effect on the folding
of the protein. Indeed, proteins can generally tolerate
only deletions of a whole domain or deletions of residues
located at the surface (in loops), where rearrangements
are more likely to be accommodated. In our case, this
tetrapeptide is located at the beginning of a b-sheet (fig.
5, red). For the protein to keep the same structure, the
four residues immediately preceding LMGD (i.e., IGKY)
would have to take their place. There is not enough space
to accommodate them smoothly, which is likely to dis-
rupt the structure.
The substitution of W308C is located on the top part
of the model shown in figure 5. C308 is likely to interact,
and to form a disulfide bridge, with C158. This inter-
action during the folding of LKB1 may result in an
aberrant three-dimensional structure with little or no
kinase activity, which is demonstrated by the autophos-
phorylation assay.
Potential Locus Heterogeneity of PJS
After searching for mutations, by means of both a
sequencing of all exons and intron-exon junctions of the
LKB1 gene and Southern blot analysis by use of the
LKB1 cDNA probe, we failed to detect any molecular
lesions in the LKB1 genes of affected individuals of In-
dian families PJS07 and PJS08. The mutations in these
two families may be in regions, either deep in the introns
or in the regulatory sequences of LKB1, that have not
been examined. Since all of the known LKB1 mutant
alleles result in either absence of LKB1 protein or elim-
ination of the kinase activity, we expect that, if affected
individuals of families PJS07 and PJS08 have mutations
in the LKB1 gene, then those mutations will result in
severe, “null” LKB1 alleles. Alternatively, and more
likely, the PJS in families PJS07 and PJS08 may be a
result of mutations in a gene different from LKB1. We
have described elsewhere that linkage analysis using
DNA samples from family PJS07 resulted in LOD scores
of 3.52 at a recombination fraction of 0, for markers
D19S877 and D19S891 on chromosome 19q13.4 (Meh-
enni et al. 1997). That analysis and the absence of LKB1
Mehenni et al.: LKB1 Mutations in PJS 1649
mutations in family PJS07 strongly suggest that there
exists a second locus for PJS syndrome. Linkage analysis
of family PJS08 gave inconclusive results, since it was
not informative for markers on 19q13.4. It is of interest
that, in the initial study by Hemminki et al. (1998), there
were PJS patients with no recognizable mutation and
that additional linkage studies (Mehenni et al. 1997;
Olschwang et al. 1998) detected families without linkage
to the LKB1 locus. Linkage analysis and positional-clon-
ing efforts are now justified, to discover potential ad-
ditional loci of PJS. These genes may uncover molecules
in kinase phosphatase–mediated metabolic pathways in-
volved in human tissue overgrowth and neoplasias (Li
et al. 1997; Steck et al. 1997; Kinzler and Vogelstein
1998).
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